Articles related to Oncology, Medical

Researchers identified the post-fast refeeding period as a distinct state with greater potential for tumor proliferation compared to the fasted or continuously fed state.

The STRIDE regimen demonstrated a 30.7% survival rate at 36 months, compared to 20.2% with sorafenib, suggesting potential long-term benefits for patients with unresectable hepatocellular carcinoma.

UnitedHealthcare’s decision to bundle G2211 into E/M payments for commercial plans signifies a shift in reimbursement strategies that oncologists need to address promptly.

The FDA’s new mandate requires all mammography facilities to inform women about their breast density, recognizing its significance in cancer risk and detection challenges.

Adjuvant durvalumab therapy led to a median overall survival of 55.9 months compared to 33.4 months with placebo in patients with limited-stage small-cell lung cancer who did not progress after chemoradiotherapy.

Cannonball pulmonary lesions on imaging should prompt a thorough investigation for underlying malignancy, particularly germ cell tumors.